Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 32,565
  • Shares Outstanding, K 36,183
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,791 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.29
  • Most Recent Earnings $-0.07 on 10/28/22
  • Next Earnings Date 12/12/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/24
See More
  • Average Estimate -0.41
  • Number of Estimates 1
  • High Estimate -0.41
  • Low Estimate -0.41
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +38.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.88 +1.14%
on 11/11/24
1.32 -32.58%
on 10/15/24
-0.45 (-33.58%)
since 10/11/24
3-Month
0.64 +39.06%
on 09/17/24
2.53 -64.82%
on 09/11/24
+0.09 (+11.25%)
since 08/12/24
52-Week
0.64 +39.06%
on 09/17/24
8.00 -88.88%
on 01/02/24
-4.56 (-83.67%)
since 11/10/23

Most Recent Stories

More News
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
Stocks in play: BriaCell Therapeutics Corp.

Provided a clinical engagement update of its pivotal Phase 3 study of Bria-IMTâ„¢ in combination with ...

BCT.TO : 0.89 (-1.11%)
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
Stocks in play: BriaCell Therapeutics Corp.

Announced U.S. FDA authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) ...

BCT.TO : 0.89 (-1.11%)
Stocks in play: BriaCell Therapeutics Corp.

Announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, ...

BCT.TO : 0.89 (-1.11%)
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.55 (+4.03%)
FULC : 3.64 (unch)
RNA : 46.73 (-0.83%)
BCTX : 0.6500 (-3.99%)
BCT.TO : 0.89 (-1.11%)
GILD : 94.35 (-2.76%)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 818.86 (-1.63%)
PBYI : 3.21 (-2.73%)
GILD : 94.35 (-2.76%)
IMGN : 31.23 (unch)
BCTX : 0.6500 (-3.99%)
BCT.TO : 0.89 (-1.11%)
Stocks in play: BriaCell Therapeutics Corp.

Announced that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics ...

BCT.TO : 0.89 (-1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast...

See More

Key Turning Points

3rd Resistance Point 0.92
2nd Resistance Point 0.92
1st Resistance Point 0.90
Last Price 0.89
1st Support Level 0.88
2nd Support Level 0.88
3rd Support Level 0.86

See More

52-Week High 8.00
Fibonacci 61.8% 5.19
Fibonacci 50% 4.32
Fibonacci 38.2% 3.45
Last Price 0.89
52-Week Low 0.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar